Efficacy and mechanism of modified Wubei powder combined with Banxia Xie Xin decoction in the treatment of reflux esophagitis
10.3760/cma.j.cn341190-20240422-00445
- VernacularTitle:乌贝散合半夏泻心汤加减治疗反流性食管炎疗效及机制研究
- Author:
Jia PANG
1
;
Rongrong XU
1
;
Min SHI
1
;
Di ZHANG
1
Author Information
1. 西安市中医医院脾胃病科，西安 710000
- Publication Type:Journal Article
- Keywords:
Esophagitis,peptic;
Esophageal sphincter,lower;
Gastrointestinal motility;
Gastroesophageal reflux;
Substance P;
Cholecystokinin;
Motilin
- From:
Chinese Journal of Primary Medicine and Pharmacy
2025;32(9):1337-1343
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the efficacy and underlying mechanism of modified Wubei powder combined with Banxia Xie Xin decoction in the treatment of reflux esophagitis (RE). Methods:A case-control study was conducted involving 82 patients with RE who received treatment at Department of Spleen and Stomach Diseases, Xi'an Hospital of Traditional Chinese Medicine from June 2022 to June 2023. The patients were randomly assigned to either a control group or an observation group, with 41 patients in each group. The control group received conventional treatment, while the observation group was given Wubei powder combined with modified Banxia Xie Xin decoction orally in addition to the conventional treatment. The traditional Chinese medicine symptom scores, lower esophageal sphincter relaxation rate (LESR), percentage of abnormal esophageal contractions, and levels of substance P (SP), cholecystokinin (CCK), motilin (MTL), gastrin (GAS), serum ghrelin, and vasoactive intestinal peptide (VIP) were compared between the two groups before treatment and at 2 and 4 weeks after treatment. Results:There was no statistically significant difference in traditional Chinese medicine symptom scores between the two groups before treatment ( P > 0.05). However, both groups showed lower symptom scores at 2 and 4 weeks after treatment compared with before treatment ( t = 6.87, 10.87, 9.59, 15.39, all P < 0.05). The observation group demonstrated significantly greater improvement in symptom scores at 2 and 4 weeks compared with the control group [(17.68 ± 2.13) vs. (23.76 ± 2.48); (11.44 ± 1.12) vs. (18.82 ± 1.85), t = 4.18, 4.35, both P < 0.05]. There were no statistically significant differences in LESR or percentage of abnormal contractions between the two groups before treatment (both P > 0.05). However, both LESR and the percentage of abnormal esophageal contractions improved at 2 and 4 weeks after treatment compared with before treatment ( t = 4.25, 5.73, 5.86, 6.49, 3.79, 4.84, 4.48, 5.56, all P < 0.05). Additionally, the observation group had significantly lower LESR at 2 and 4 weeks compared with the control group [(71.62 ± 6.37)% vs. (75.46 ± 6.89)%, (64.92 ± 5.82)% vs. (70.78 ± 6.45)%, t = 5.43, 5.86, both P < 0.05]. The percentage of abnormal esophageal contractions was also significantly lower in the observation group [(45.28 ± 5.18)% vs. (59.56 ± 5.84)%; (33.53 ± 4.24)% vs. (47.74 ± 5.31)%, t = 6.08, 7.24, both P < 0.05]. Before treatment, there were no statistically significant differences in levels of SP, MTL, GAS, or CCK between the two groups (all P > 0.05). The levels of SP, MTL, GAS, and CCK improved in both groups at 2 and 4 weeks compared with before treatment ( t = 4.67, 7.15, 7.24, 9.87, 3.62, 5.85, 4.58, 7.17, 3.55, 5.41, 5.42, 6.89, 3.53, 5.43, 5.39, 6.82, all P < 0.05). Furthermore, the observation group had significantly higher levels of SP, MTL, and GAS at 2 and 4 weeks compared with the control group ( t = 3.65, 4.12, 3.86, 4.25, 4.48, 5.36, all P < 0.05), while CCK levels were significantly lower in the observation group ( t = 4.38, 4.51, both P < 0.05). There were no statistically significant differences in ghrelin or VIP levels between the two groups before treatment (both P > 0.05). However, both ghrelin and VIP levels improved in both groups at 2 and 4 weeks after treatment compared with before treatment ( t = 3.35, 3.72, 3.69, 4.28, 3.76, 4.88, 4.11, 5.69, all P < 0.05). Additionally, the observation group had significantly higher levels of ghrelin compared with the control group ( t = 3.43, 4.11, both P < 0.05), while VIP levels were significantly lower in the observation group ( t = 4.59, 5.71, both P < 0.05). Conclusions:The addition of modified Wubei powder combined with Banxia Xie Xin decoction to conventional treatment can considerably alleviate clinical symptoms in patients with RE and improve esophageal pressure. Furthermore, this combined therapy can effectively regulate serum levels of SP, CCK, MTL, GAS, ghrelin, and VIP, thereby modulating the contraction and relaxation of gastrointestinal smooth muscle, enhancing lower esophageal sphincter pressure, and reducing reflux.
